TW202313563A - 苯并氧氮呯噁唑啶酮化合物之製備方法 - Google Patents

苯并氧氮呯噁唑啶酮化合物之製備方法 Download PDF

Info

Publication number
TW202313563A
TW202313563A TW111119945A TW111119945A TW202313563A TW 202313563 A TW202313563 A TW 202313563A TW 111119945 A TW111119945 A TW 111119945A TW 111119945 A TW111119945 A TW 111119945A TW 202313563 A TW202313563 A TW 202313563A
Authority
TW
Taiwan
Prior art keywords
formula
compound
optionally substituted
salt
alkyl
Prior art date
Application number
TW111119945A
Other languages
English (en)
Chinese (zh)
Inventor
雷米 安吉洛
托拜斯 布魯奇
法蘭西斯 葛賽琳
翀 韓
阿爾佛瑞德 史塔茲
Original Assignee
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司 filed Critical 美商建南德克公司
Publication of TW202313563A publication Critical patent/TW202313563A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/04—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof by substitution of hydrogen atoms by sulfo or halosulfonyl groups
    • C07C303/06—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof by substitution of hydrogen atoms by sulfo or halosulfonyl groups by reaction with sulfuric acid or sulfur trioxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/72—Copper
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW111119945A 2021-05-28 2022-05-27 苯并氧氮呯噁唑啶酮化合物之製備方法 TW202313563A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163194382P 2021-05-28 2021-05-28
US63/194,382 2021-05-28

Publications (1)

Publication Number Publication Date
TW202313563A true TW202313563A (zh) 2023-04-01

Family

ID=82156627

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111119945A TW202313563A (zh) 2021-05-28 2022-05-27 苯并氧氮呯噁唑啶酮化合物之製備方法

Country Status (13)

Country Link
US (1) US20240166595A1 (cg-RX-API-DMAC10.html)
EP (1) EP4347574A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520479A (cg-RX-API-DMAC10.html)
KR (1) KR20240013791A (cg-RX-API-DMAC10.html)
CN (1) CN117377660A (cg-RX-API-DMAC10.html)
AR (1) AR125993A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022282440A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023024764A2 (cg-RX-API-DMAC10.html)
CA (1) CA3220273A1 (cg-RX-API-DMAC10.html)
IL (1) IL308457A (cg-RX-API-DMAC10.html)
MX (1) MX2023013919A (cg-RX-API-DMAC10.html)
TW (1) TW202313563A (cg-RX-API-DMAC10.html)
WO (1) WO2022251567A1 (cg-RX-API-DMAC10.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI423980B (zh) 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯pi3k抑制劑化合物及使用方法
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
PL3851441T3 (pl) * 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
AU2019276514B2 (en) * 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN109265408B (zh) * 2018-12-11 2020-09-01 上海皓元生物医药科技有限公司 二氟甲基取代噁烷-2-酮的合成方法

Also Published As

Publication number Publication date
EP4347574A1 (en) 2024-04-10
MX2023013919A (es) 2023-12-08
CA3220273A1 (en) 2022-12-01
KR20240013791A (ko) 2024-01-30
JP2024520479A (ja) 2024-05-24
WO2022251567A1 (en) 2022-12-01
CN117377660A (zh) 2024-01-09
AU2022282440A1 (en) 2023-11-16
BR112023024764A2 (pt) 2024-02-15
IL308457A (en) 2024-01-01
US20240166595A1 (en) 2024-05-23
AR125993A1 (es) 2023-08-30

Similar Documents

Publication Publication Date Title
EP3752496B1 (en) Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
TWI846704B (zh) 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程,包括其使用方法
EP3956320B1 (en) Dihydroorotate dehydrogenase inhibitors
TW202528314A (zh) Kras調節劑
EP3851441B1 (en) Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
TW201829422A (zh) 7H-吡咯并[2,3-d]嘧啶衍生物的製造方法及其合成中間體
EP3876942A1 (en) Inhibitors of human immunodeficiency virus replication
US9975856B2 (en) Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
WO2023150653A1 (en) Process for synthesis of quinazoline compounds
KR102797099B1 (ko) 2-[(3r)-3-메틸모르폴린-4-일]-4-(1-메틸-1h-피라졸-5-일)-8-(1h-피라졸-5-일)-1,7-나프티리딘의 제조 방법
EP1602646A1 (en) Processes for producing cyclic benzamidine derivative
CN112654606A (zh) 三氮唑类化合物及其制备方法与用途
CN114630826A (zh) 作为二氢乳清酸脱氢酶(DHODH)抑制剂用于治疗癌症、自身免疫性和炎性疾病的氟化喹啉、喹喔啉和苯并[b][1,4]噁嗪衍生物
JP2024520479A (ja) ベンゾオキサゼピンオキサゾリジノン化合物の調製のための方法
JP7756718B2 (ja) オクタヒドロイソキノリニル誘導体
JP2025510230A (ja) Shp2阻害剤の調製プロセス
HK40106404A (en) Process for the preparation of benzoxazepin oxazolidinone compounds
WO2026090336A1 (en) Processes for preparing kras inhibitors
CA3247483A1 (en) SPLEEN TYROSINE KINASE INHIBITORS
HK40041775A (en) Triazole compounds, and preparation method thereof and use
HK40104844A (en) Solid forms and processes for preparing fused tricyclic compounds, including methods of their use
HK40043126B (en) Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
HK40043126A (en) Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
HK40012772B (en) Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
HK40012772A (en) Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide